Immunotherapy biologics represent a transformative approach in treating cancer and infections by using biological molecules to strengthen the immune system’s response. Biologics such as monoclonal antibodies target specific proteins on the surface of pathogenic cells, either marking them for immune destruction or blocking signals that promote their growth. An innovative approach is Bispecific T-cell Engagers, which act as a bridge between T-cells and the target cells, enabling T-cells to recognize and kill the pathogen more effectively. Another breakthrough is CAR-T cell therapy, where a patient's T-cells are genetically engineered to better identify and destroy pathogenic cells upon reintroduction into the body. Further, biologics like cytokines and monoclonal antibodies are used to boost immune defenses or directly neutralize pathogens. These biologics provide a more targeted, tailored treatments and potentially longer-lasting alternative to conventional treatments like chemotherapy or antibiotics or antivirals, making them powerful tools in managing both cancer and difficult-to-treat infections.
Current biologics have demonstrated remarkable efficacy in treatment of hematological cancers but remain less effective for treatment of solid tumors. This could be for several reasons including lack of good targets for solid tumors, persistence of therapies in patients, T cell exhaustion. The immunosuppressive tumor microenvironment (TME) can also affect the efficacy of current therapies. Autologous cell therapies take several weeks to manufacture which reduces the number of patients this therapy is currently able to help. Manufacturing of biologics is extremely complicated, and biologics have cold chain requirements which increases the cost of therapy. This makes them inaccessible to a significant population. The main challenge which we would like to address in this Research Topic is the development of novel biologics and technologies which address both scientific and logistical challenges associated with current biologics therapy for cancer and infectious diseases.
The main goal of this Research Topic is to gain a better understanding of novel technologies and biologics being developed to tackle the myriad challenges affecting the use of biologics for cancer as well as infectious disease. We wish to assemble a diverse array of manuscripts which would educate the readers about cutting-edge, multidisciplinary approaches being developed which are either an improvement over current standard of care therapy or make them accessible to a wider patient population. We are excited to receive submissions of Original Research, Reviews, Mini-Reviews, Methods, Case reports and Perspective articles which cover but are not limited to:
1. Biologics which engage innate and/or adaptive immunity
2. Targeted delivery of biologics to reduce toxicities
3. Novel delivery methods (for example nucleic acids/LNP/viral vectors)
4. Improvements in manufacturing of autologous cell therapies including T cells, NK cells or Macrophages/Monocytes
5. Combination therapies to overcome therapeutic resistance
6. Biologics which address Antimicrobial Resistance (AMR)
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Biologics, Adaptive Immunity, Cancer Infectious Disease Immunotherapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Immunotherapy biologics represent a transformative approach in treating cancer and infections by using biological molecules to strengthen the immune system’s response. Biologics such as monoclonal antibodies target specific proteins on the surface of pathogenic cells, either marking them for immune destruction or blocking signals that promote their growth. An innovative approach is Bispecific T-cell Engagers, which act as a bridge between T-cells and the target cells, enabling T-cells to recognize and kill the pathogen more effectively. Another breakthrough is CAR-T cell therapy, where a patient's T-cells are genetically engineered to better identify and destroy pathogenic cells upon reintroduction into the body. Further, biologics like cytokines and monoclonal antibodies are used to boost immune defenses or directly neutralize pathogens. These biologics provide a more targeted, tailored treatments and potentially longer-lasting alternative to conventional treatments like chemotherapy or antibiotics or antivirals, making them powerful tools in managing both cancer and difficult-to-treat infections.
Current biologics have demonstrated remarkable efficacy in treatment of hematological cancers but remain less effective for treatment of solid tumors. This could be for several reasons including lack of good targets for solid tumors, persistence of therapies in patients, T cell exhaustion. The immunosuppressive tumor microenvironment (TME) can also affect the efficacy of current therapies. Autologous cell therapies take several weeks to manufacture which reduces the number of patients this therapy is currently able to help. Manufacturing of biologics is extremely complicated, and biologics have cold chain requirements which increases the cost of therapy. This makes them inaccessible to a significant population. The main challenge which we would like to address in this Research Topic is the development of novel biologics and technologies which address both scientific and logistical challenges associated with current biologics therapy for cancer and infectious diseases.
The main goal of this Research Topic is to gain a better understanding of novel technologies and biologics being developed to tackle the myriad challenges affecting the use of biologics for cancer as well as infectious disease. We wish to assemble a diverse array of manuscripts which would educate the readers about cutting-edge, multidisciplinary approaches being developed which are either an improvement over current standard of care therapy or make them accessible to a wider patient population. We are excited to receive submissions of Original Research, Reviews, Mini-Reviews, Methods, Case reports and Perspective articles which cover but are not limited to:
1. Biologics which engage innate and/or adaptive immunity
2. Targeted delivery of biologics to reduce toxicities
3. Novel delivery methods (for example nucleic acids/LNP/viral vectors)
4. Improvements in manufacturing of autologous cell therapies including T cells, NK cells or Macrophages/Monocytes
5. Combination therapies to overcome therapeutic resistance
6. Biologics which address Antimicrobial Resistance (AMR)
Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this Research Topic.
Keywords:
Biologics, Adaptive Immunity, Cancer Infectious Disease Immunotherapy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.